Molecular imaging of aurora kinase A (AURKA) expression: Synthesis and preclinical evaluation of radiolabeled alisertib (MLN8237)

Abstract

IntroductionSurvival of patients after resection of colorectal cancer liver metastasis (CRCLM) is 36%–58%. Positron emission tomography (PET) tracers, imaging the expression of prognostic biomarkers, may contribute to assign appropriate management to individual patients. Aurora kinase A (AURKA) expression is associated with survival of patients after CRCLM resection. MethodsWe synthesized [3H]alisertib and [11C]alisertib, starting from [3H]methyl nosylate and [11C]methyl iodide, respectively. We measured in vitro uptake of [3H]alisertib in cancer cells with high (Caco2), moderate (A431, HCT116, SW480) and low (MKN45) AURKA expression, before and after siRNA-mediated AURKA downmodulation, as well as after inhibition of P-glycoprotein (P-gp) activity. We measured in vivo uptake and biodistribution of [11C]alisertib in nude mice, xenografted with A431, HCT116 or MKN45 cells, or P-gp knockout mice. Results[3H]Alisertib was synthesized with an overall yield of 42% and [11C]alisertib with an overall yield of 23%±9% (radiochemical purity ≥99%). Uptake of [3H]alisertib in Caco2 cells was higher than in A431 cells (P=.02) and higher than in SW480, HCT116 and MKN45 cells (P<.01). Uptake in A431 cells was higher than in SW480, HCT116 and MKN45 cells (P<.01). Downmodulation of AURKA expression reduced [3H]alisertib uptake in Caco2 cells (P<.01). P-gp inhibition increased [3H]alisertib uptake in Caco2 (P<.01) and MKN45 (P<.01) cells. In vivo stability of [11C]alisertib 90min post-injection was 94.7%±1.3% and tumor-to-background ratios were 2.3±0.8 (A431), 1.6±0.5 (HCT116) and 1.9±0.5 (MKN45). In brains of P-gp knockout mice [11C]alisertib uptake was increased compared to uptake in wild-type mice (P<.01) ConclusionsRadiolabeled alisertib can be synthesized and may have potential for the imaging of AURKA, particularly when AURKA expression is high. However, the exact mechanisms underlying alisertib accumulation need further investigation. Advances in knowledge and implications for patient careRadiolabeled alisertib may be used for non-invasively measuring AURKA protein expression and to stratify patients for treatment accordingly.